Theradigm, Inc.

Cell-based therapies for CNS (central nervous system) disorders

Theradigm, Inc. is a privately held, portfolio company of Toucan Capital Fund II with focus on the development of cell-based therapies for the treatment of central nervous system (CNS) disorders.

Alan K. Smith, PhD, President & COO
Padmavathy Vanguri, Ph.D., Director, Neurobiology
Ken Moseley, General Counsel Business Development & Licensing
Amanda Hendricks, Human Resources

1448 S. Rolling Road
Baltimore, MD 21227
USA
Phone: +1-410-455-5697
Fax: +1-410-455-5551

Theradigm’s current research activities are focused on the establishment of new human NSC lines and development of methods to improve the growth rate and expansion potential of NSCs. Bone Marrow Stromal Cells (BMSC) as an alternative source of adult stem cells can differentiate into various non-hematopoietic tissues when implanted in vivo. Theradigm uses BMSCs for the treatment of neurological diseases.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.